iRhythm Technologies, Inc. has announced findings from the AVALON study, presented at HRS2025, highlighting the effectiveness of its Zio long-term continuous monitoring (LTCM) service in a younger, ...
iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...
SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC) (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio ® monitor, its ...
Zio LTCM also outperformed other ACM categories: even after accounting for baseline patient differences, Holter, MCT monitoring and AEM were 1.4, 3.0, and 4.3 times more likely to result in retesting ...
iRhythm Technologies recently launched its next-generation Zio monitor and enhanced Zio long-term continuous monitoring service in the United States. The San Francisco, CA-based company touts an ...
A new study from the Scripps Translational Science Institute, published in the American Journal of Medicine, shows that iRhythm's Zio patch, a wireless adhesive heart monitor patch, detects more ...
The clinical experts who had experience of using Zio XT explained that it offers continuous monitoring over 14 days and is well accepted by patients. Experts commented on how easy it is to fit and ...
SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the U.S. launch of its next-generation Zio® monitor and enhanced Zio® long-term continuous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results